Amanda Edmond, PA-C, of Banner MD Anderson Cancer Center at Banner Gateway Medical Center, reviews early COPERNICUS data on subcutaneous amivantamab plus lazertinib in EGFR-mutated non-small cell lung cancer and how proactive dermatologic and venous thromboembolism prophylaxis changes the day-to-day experience for advanced practice providers and their patients.